参考文献_

[1]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南.中华心血管病杂志，2007，35：390-413.

[2]中华医学会心血管病学分会循证医学评论专家组，中国老年学学会心脑血管病专业委员会.三酰甘油增高的血脂异常防治中国专家共识.中华心血管病杂志，2011，39：793-796.

[3]中华医学会心血管病学分会，中国老年学学会心脑血管病专业委员会.血脂相关性心血管剩留风险控制的中国专家共识.中华心血管病杂志，2012，40：547-553.

[4]Executive summary of the third report of the national cholesterol education program(NCEP)expert panel on detection,evaluation and treatment of high blood cholesterol in adults(ATPⅢ).JAMA,2001,285:2486-2497.(https://www.daowen.com)

[5]Pearson TA,Denke MA,McBride PE,et al.A community-based randomized trial of ezetimibe added to statin to attain NCEP ATPⅢgoals for LDL cholesterol in hypercholestero-lemic patients:the ezetimibe added to statin for effectiveness(EASE)trial.Mayo Clin Proc,2005,80:587-595.

[6]European Association for Cardiovascular Prevention&Rehabilitation,Reiner Z,Catapano AL,et al.ESC/EAS Guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the european society of cardiology(ESC)and the european atherosclerosis society(ESC).Eur Heart J,2011,32:1769-1818.

[7]Leiter LA,Lundman P,da Silva PM,et al.Persistent lipid abnormalities in stain-treated patients with diabetes mellirus in Europe and Canada:results of the dyslipidamia international study.Diabet Med,2011,28:1343-1351.